MARKET

DNLI

DNLI

Denali Therapeut
NASDAQ
18.16
-1.58
-7.98%
After Hours: 18.28 +0.12 +0.66% 18:55 03/27 EDT
OPEN
19.59
PREV CLOSE
19.74
HIGH
19.74
LOW
18.10
VOLUME
3.07M
TURNOVER
--
52 WEEK HIGH
23.77
52 WEEK LOW
10.57
MARKET CAP
2.88B
P/E (TTM)
-6.1172
1D
5D
1M
3M
1Y
5Y
1D
Denali Therapeutics Is Maintained at Overweight by Morgan Stanley
Dow Jones · 1d ago
Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $42
Benzinga · 1d ago
Denali Therapeutics Is Maintained at Buy by Goldman Sachs
Dow Jones · 1d ago
Denali Therapeutics Price Target Raised to $40.00/Share From $35.00 by Goldman Sachs
Dow Jones · 1d ago
Goldman Sachs Maintains Buy on Denali Therapeutics, Raises Price Target to $40
Benzinga · 1d ago
Denali Therapeutics Is Maintained at Buy by Stifel
Dow Jones · 1d ago
Stifel Maintains Buy on Denali Therapeutics, Raises Price Target to $41
Benzinga · 1d ago
Arm Holdings To Rally Over 27%? Here Are 10 Top Analyst Forecasts For Thursday
Benzinga · 2d ago
More
About DNLI
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.

Webull offers Denali Therapeutics Inc stock information, including NASDAQ: DNLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DNLI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DNLI stock methods without spending real money on the virtual paper trading platform.